Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7772
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients ; day:3 ; month:11 ; year:2018 ; pages:1-12
International journal of clinical oncology ; (3.11.2018), 1-12
- Classification
-
Medizin, Gesundheit
- Creator
-
Masuda, Norikazu
Inoue, Kenichi
Nakamura, Rikiya
Rai, Yoshiaki
Mukai, Hirofumi
Ohno, Shinji
Hara, Fumikata
Mori, Yuko
Hashigaki, Satoshi
Muramatsu, Yasuaki
Nagasawa, Takashi
Umeyama, Yoshiko
Huang, Xin
Iwata, Hiroji
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10147-018-1359-3
- URN
-
urn:nbn:de:101:1-2018122219284078744104
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
26.02.2000, 2:32 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Masuda, Norikazu
- Inoue, Kenichi
- Nakamura, Rikiya
- Rai, Yoshiaki
- Mukai, Hirofumi
- Ohno, Shinji
- Hara, Fumikata
- Mori, Yuko
- Hashigaki, Satoshi
- Muramatsu, Yasuaki
- Nagasawa, Takashi
- Umeyama, Yoshiko
- Huang, Xin
- Iwata, Hiroji
- SpringerLink (Online service)
Other Objects (12)
Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients
Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients
Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib